WHAT IS CLAIMED IS:

1. Use of an NAE inhibitor chosen from ((1S,2S,4R)-4-(4-{{1S)-2,3-dihydro-1H-inden-1-ylamino}-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl}methyl sulfamate or a pharmaceutically acceptable salt thereof, or {(1*S*,2*S*,4*R*)-4-[(6-{[(1*R*,2*S*)-5-chloro-2-methoxy-2,3 -dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer, said treating comprising administering the NAE inhibitor in combination with a hypomethylating agent chosen from azacitidine or a pharmaceutically acceptable salt thereof, or decitabine or a pharmaceutically acceptable salt thereof.

2. Use of a hypomethylating agent chosen from azacitidine or a pharmaceutically acceptable salt thereof, or decitabine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer, said treating comprising administering the hypomethylating agent in combination with an NAE inhibitor chosen from ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or a pharmaceutically acceptable salt thereof, or {(1*S*,2*S*,4*R*)-4-[(6-{[(1*R*,2*S*)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate, or a pharmaceutically acceptable salt thereof.

3. Use of an NAE inhibitor chosen from ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino}-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl}methyl sulfamate or a pharmaceutically acceptable salt thereof, or {{1*S*,2*S*,4*R*)-4-[(6-{[(1*R*,2*S*)-5-chloro-2-methoxy-2,3 -dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate, or a pharmaceutically acceptable salt thereof, and a hypomethylating agent chosen from azacitidine or a pharmaceutically acceptable salt thereof, or decitabine or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer.

4. The use of any one of claims 1 to 3, wherein the NAE inhibitor is ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-2-hydroxycyclopentyl)methyl sulfamate or a pharmaceutically acceptable salt thereof.

5. The use of any one of claims 1 to 3, wherein the NAE inhibitor is {(1*S*,2*S*,4*R*)-4-[{6-{[(1*R*,2*S*)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate, or a pharmaceutically acceptable salt thereof.

6. The use of claim 4, wherein the treating comprises administering ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyctopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof on each of Days 1, 3, and 5 of a 28-day cycle.

7. The use of claim 6, wherein the treating comprises administering ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycydopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof at a dose of about 20 mg/m^2.

8. The use of claim 6, wherein the treating comprises administering ((1S,2S,4R)-4-(4-((1S}-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof at a dose of about 30 mg/m^2.

9. The use of claim 6, wherein the treating comprises administering {(1S,2S,4R)-4-(4-{(1S}-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof at a dose of about 40 mg/m^2.

10. The use of claim 6, wherein the treating comprises administering {(1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyc!opentyl)methyl sulfamate or pharmaceutically acceptable salt thereof at a dose of about 50 mg/m^2.

11. The use of claim 6, wherein the treating comprises administering ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof at a dose ranging from about 20 mg/m^2 to about 30 mg/m^2.

12. The use of any one of claims 6 to 11, wherein the treating comprises administering ((1S,2S,4R)-4-(4-((1S}-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof intravenously.

13. The use of any one of claims 6 to 11, wherein the treating comprises administering ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or pharmaceutically acceptable salt thereof subcutaneously.

14. The use of any one of claims 1 to 13, wherein the hypomethylating agent is azacitidine or a pharmaceutically acceptable salt thereof.

15. The use of claim 14, wherein the treating comprises administering azacitidine or a pharmaceutically acceptable salt thereof on each of Days 1, 2, 3, 4, 5, 8 and 9 of a 28-day cycle.

16. The use of claim 15, the treating comprises administering azacitidine or a pharmaceutically acceptable salt thereof at a dose of about 75 mg/m^2.

17. The use of claim 15 or 16, wherein the treating comprises administering the azacitidine or pharmaceutically acceptable salt thereof subcutaneously.

18. The use of claim 15 or 16, wherein the treating comprises administering azacitidine or pharmaceutically acceptable salt thereof intravenously.

19. The use of any one of claims 1 to 13, wherein the hypomethylating agent is decitabine or a pharmaceutically acceptable salt thereof.

20. The use of any one of claims 1 to 19, wherein the treating comprises administering the NAE inhibitor or pharmaceutically acceptable salt thereof and the hypomethylating agent or pharmaceutically acceptable salt thereof in a single dosage form.

21. The use of any one of claims 1 to 19, wherein the treating comprises administering the NAE inhibitor or pharmaceutically acceptable salt thereof and the hypomethylating agent or pharmaceutically acceptable salt thereof in separate dosage forms.

22. The use of any one of claims 1 to 21, wherein the cancer is a hematologic malignancy.

23. The use of claim 22, wherein the cancer is acute myeloid Ieukemia (AML).

24. The use of claim 22, wherein the cancer is myelodysplastic syndromes (MDS).

25. The use of claim 24, wherein the myelodysp!astic syndromes (MDS) are diagnosed as any of refractory anemia (RA), refractory anemia with ringed siderblasts (RARS), (refractory anemia with excess blasts (RAEB), and RAEB in transformation (RAEB-T).

26. The use of claim 25, wherein the diagnosis is predominantly one type of myelodysplastic syndromes.

27. The use of claim 25, wherein the diagnosis is more than one type of myelodysplastic syndromes.

28. The use of claim 22, wherein the cancer is diagnosed as any of chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic Ieukemia (CLL), Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), T-cell lymphoma, multiple myeloma (MM), Waldenstrom's macroglobulinemia, myelodysplastic syndromes (MDS), and myeloproliferative syndromes.

29. The use of claim 28, wherein the diagnosis is predominantly one type of cancer.

30. The use of claim 28, wherein the diagnosis is more than one type of cancer.

31. A kit for treating cancer in a subject in recognized need thereof comprising

- at least one medicament comprising at least one dose of an NAE inhibitor chosen from ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate or a pharmaceutically acceptable salt thereof, or {(1*S*,2*S*,4*R*)-4-[(6-{[(1*R*,2*S*)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate or a pharmaceutically acceptable salt thereof, and

- at least one medicament comprising at least one dose of a hypomethylating agent chosen from azacitidine or a pharmaceutically acceptable salt thereof, or decitabine or a pharmaceutically acceptable salt thereof;

said kit for treating cancer further comprising dosing instructions for administering the medicaments for treatment of the subject in recognized need thereof.

32. A use according to claim 1, substantially as herein described or exemplified.

33. A use according to claim 2, substantially as herein described or exemplified.

34. A use according to claim 3, substantially as herein described or exemplified.

35. A kit according to claim 31, substantially as herein described or exemplified.